Kevin McCulloch, president and chief operating officer of Xeris Biopharma Holdings, sold 15,000 shares of common stock on September 1, 2026, at a weighted average price of $8.4872 per share, generating gross proceeds of $127,308.
The transaction was executed under a Rule 10b5-1 trading plan McCulloch adopted on September 4, 2025. At the time of the sale, Xeris Biopharma’s stock was valued at $8.43, down 0.12% in after-hours trading.
McCulloch retains direct ownership of 1,639,208 shares of Xeris Biopharma common stock. An additional 25,000 shares are held indirectly by his spouse, though McCulloch disclaims beneficial ownership beyond his pecuniary interest in those shares.
Xeris Biopharma reported second-quarter 2026 revenue of $92.1 million, exceeding Wall Street estimates. The company posted a loss of $0.18 per share, missing analyst expectations for a $0.01 per share profit. Management highlighted record commercial momentum, citing strong demand for RECORLEV and a rebound in Gvoke sales. A one-time non-cash GAAP charge related to convertible note remeasurement was also noted.
Xeris Biopharma’s stock has delivered a 38% return over the past six months, though InvestingPro data currently ranks it as among the most overvalued in its coverage universe based on fair-value metrics.
